Literature DB >> 23493582

On biomarkers and pathways in rectal cancer: What's the target?

Gabriele Zoppoli1, Valter Ferrando, Stefano Scabini.   

Abstract

In spite of tremendous progresses in surgical and chemo-radiotherapeutic regimens, rectal cancer still suffers from high relapse and mortality rates, and metastatic disease is incurable. Here we assess some of the most recent and validated biomarkers and potential targets studied in rectal cancer, and provide comments to a recent monographic topic covering several aspects of colorectal cancer, published in Current Cancer Drug Targets.

Entities:  

Keywords:  Biological markers; Chemotherapy; Colorectal surgery; Rectal cancer; Targeted molecular therapy

Year:  2012        PMID： 23493582      PMCID： PMC3596522          DOI： 10.4240/wjgs.v4.i12.275

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  26 in total

1.  Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Authors:  Torsten Liersch; Claus Langer; B Michael Ghadimi; Bettina Kulle; Daniela E Aust; Gustavo B Baretton; Wolfgang Schwabe; Peter Häusler; Heinz Becker; Christiane Jakob
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

Review 2.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

Review 3.  High-throughput RNAi screening in cultured cells: a user's guide.

Authors:  Christophe J Echeverri; Norbert Perrimon
Journal:  Nat Rev Genet       Date:  2006-05       Impact factor: 53.242

4.  The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis.

Authors:  Jordi Giralt; Manuel de las Heras; Laura Cerezo; Aranzazu Eraso; Edurado Hermosilla; Dolores Velez; Juan Lujan; Eloi Espin; Jose Rosello; Joaquin Majó; Sergi Benavente; Manel Armengol; I de Torres
Journal:  Radiother Oncol       Date:  2005-02       Impact factor: 6.280

5.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

Authors:  B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

6.  VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy.

Authors:  Inti Zlobec; Russell Steele; Carolyn C Compton
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

7.  Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles.

Authors:  Toshiaki Watanabe; Yasuhiro Komuro; Tomomichi Kiyomatsu; Takamitsu Kanazawa; Yoshihiro Kazama; Junichiro Tanaka; Toshiaki Tanaka; Yoko Yamamoto; Masatoshi Shirane; Tetsuichiro Muto; Hirokazu Nagawa
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

Authors:  C Bengala; S Bettelli; F Bertolini; S Salvi; S Chiara; C Sonaglio; L Losi; N Bigiani; G Sartori; C Dealis; N Malavasi; R D'Amico; G Luppi; B Gatteschi; A Maiorana; P F Conte
Journal:  Ann Oncol       Date:  2008-12-18       Impact factor: 32.976

9.  An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

Authors:  Joe J Stephenson; Charles Gregory; Howard Burris; Tim Larson; Udit Verma; Allen Cohn; Jeffrey Crawford; Roger B Cohen; Julie Martin; Peggy Lum; Xinqun Yang; Rafael G Amado
Journal:  Clin Colorectal Cancer       Date:  2009-01       Impact factor: 4.481

10.  p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.

Authors:  E Lopez-Crapez; F Bibeau; S Thézenas; M Ychou; J Simony-Lafontaine; A Thirion; D Azria; J Grenier; P Senesse
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640
View more
  2 in total

1.  Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Authors:  Muhammad Wasif Saif
Journal:  Cancer Manag Res       Date:  2013-06-11       Impact factor: 3.989

2.  Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma.

Authors:  Lorenzo Ferrando; Gabriella Cirmena; Anna Garuti; Stefano Scabini; Federica Grillo; Luca Mastracci; Edoardo Isnaldi; Ciro Marrone; Roberta Gonella; Roberto Murialdo; Roberto Fiocca; Emanuele Romairone; Alberto Ballestrero; Gabriele Zoppoli
Journal:  PLoS One       Date:  2020-02-05       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.